A Phase II Study of the Efficacy and Safety of Oral Selinexor in Recurrent Glioblastoma

Abstract

At 80 mg weekly, single-agent selinexor induced responses and clinically relevant PFS6 with manageable side effects requiring dose reductions. Ongoing trials are evaluating safety and efficacy of selinexor in combination with other therapies for newly diagnosed or recurrent glioblastoma.